¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ;vclAsJ  
LEngZ~sV/  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© D^s0EW- E  
q AVfbcb  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Bb[0\Hs7  
b)hOzx  
1.Co-stimulators (or co-stimulating molecules) txfw Lqx  
mERZ_[a2  
2.NK-kB y5Wqu9C\Io  
3Ra\2(bR  
3.Immunoglobulin superfamily wz0$g4  
io Y\8i  
4.antigen-presenting cell (APC) ;*4tVp,  
dI ZTLb"a  
5.death domain .xz,pn}  
X|damI%  
6.CCR and CXCR P$6f+{  
.f !] @"\  
7.Lectin (or mitogen) BtpjQNN  
Vi? ~0.Z%  
8.Clusters of differentiation, CD) p[@oF5M  
QK3j_'F=E  
9.B7 family sPE)m_u  
bDZKQ&  
10.Cytotoxic T lymphocyte, CTL) @1/}-.(n  
] EVe@  
11.IL-15 and IL-15 receptor (IL-15R) S QM(8*:X  
N+C)/EN$  
12.MHC restriction SZK)q   
v`_i1h9p{  
13.Affinity-chromatography l)i &ATvCE  
 *_ { l  
14.Cyctosprin A, CsA 0?6 If+AC  
lC /Hib  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) e\^g|60f_  
_d\u!giy  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© (?!(0Ywbg  
;e~{TkD  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 %0+h  
_>gXNS r4u  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ z<yNG/M1>U  
aDN6MZM  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ KJ0xp h f  
:Wyn+  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Xr@l+zr  
( Lok  
ÃâÒßѧרҵ£º .])>A')r  
KMxNH,5  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 3~[`[4n^  
`G=ztL!gq  
Ïû»¯ÄÚ¿Æ£º S3ab0JM  
qYgwyj=4  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ RLYU\@kK?  
dWsT Jyx~  
ѪҺ²¡Ñ§×¨Òµ£º |eH wp  
]&Y#) ebs  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»